PUT/GILEAD SCIENCES/70/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 11:57:23 31/05/2024 pm IST | ||
| 0.64 EUR | +4.40% |
|
| 1 month | +22.37% | ||
| 3 months | +158.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.64 | +4.40% |
| 30/24/30 | 0.613 | -8.78% |
| 29/24/29 | 0.672 | +9.80% |
| 28/24/28 | 0.612 | +28.84% |
| 27/24/27 | 0.475 | -2.26% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Goldman Sachs |
| WKN | GZ8VJY |
| ISIN | DE000GZ8VJY2 |
| Date issued | 16/02/2023 |
| Strike | 70 $ |
| Maturity | 21/06/2024 (20 Days) |
| Parity | 10 : 1 |
| Emission price | 0.36 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.78 € |
|---|---|
| Lowest since issue | 0.065 € |
| Spread | 0.01 € |
| Spread % | 1.64% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Warrants
- Warrant
